The U.S. Court of Appeals for the Federal Circuit confirmed a ruling from a Delaware federal court regarding Alkem Laboratories. The court decided that Alkem’s generic version of the antibiotic Firvanq does not infringe upon the patent held by Azurity Pharmaceuticals. This decision maintains the lower court’s stance, allowing Alkem to proceed with its generic product.
The decision underscores ongoing discussions about patent rights within the pharmaceutical industry, where generic manufacturers often challenge existing patents to bring more affordable medication options to the market. For further details on this decision, you can refer to the full article on Law360.